Biologic drugs targeting IL-17 (e.g., secukinumab, ixekizumab) showed consistent efficacy and are currently approved for treatment in peripheral and axial SpA, while they have no effect or can even exacerbate IBD, further confirming the dual effect of these cytokines in systemic and intestinal mucosal inflammation [29,30]. The gene discussed is IL17A; the disease is inflammatory bowel disease.